AlloVir soars after FDA grants designation to its therapy

Kalaris Therapeutics

20/04/2022 15:04

(Updates)
    ** Drug developer's shares  ALVR.O  climbs 45% to $7.86; top
pct gainer on the Nasdaq    
    ** AlloVir says U.S. Food and Drug Administration has
granted Regenerative Medicine Advanced Therapy designation to
its experimental therapy, posoleucel, for prevention of
infections and disease from six viruses  urn:newsml:reuters.com:*:nBw9sHx98a
    ** Says it has started Phase 3 multi-virus prevention trial
in March 2022 
    ** Stock trading above its 50 DMA price, but below 150 DMA
and 200 DMA price; ALVR still way off its 52-week high of $26.41
touched on Oct. 1 
    ** More than 33.4 mln shares traded in the first 25 mins, 25
DMA volume is 269,018 shares; Co has about 65.4 mln shares
outstanding
    ** Up to Tuesday's close, stock had fallen 59% YTD 

 (Reporting by Ankur Banerjee)